More than 95% of CML patients express fusion variants of BCR::ABL1, with the encoded BCR-ABL1 proteins being constitutively activated tyrosine kinases that drive the leukemic transformation associated with CML via a number of mechanisms [32]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.